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Abstract: Novel anxiolytic medications are necessary to broaden treatment therapy. Thus, the aim of the present 
study was to compare the clinically effective anxiolytic, diazepam with the novel 3,4-dimethoxyphenylethylamine 
derivates. The novel 3,4-dimethoxyphenylethylamine derivates (PK, 0.1, 1.0, 10.0 mg/kg, i.p.) and diazepam (1.0 
mg/kg) were injected acutely or chronically in animals subjected to the black-white model and the open field test. 
The acute administration of PK-2122 (0.1 mg/kg, i.p.) exerted anxiogenic-like effect, while in the middle or high 
doses PK-2122 exerted anxiolytic-like effect compared with the control group (p<0.05). The repeated treatment 
with PK-2111 was followed by anxiolytic-like effect in doses of 0.1 or 1.0 mg/kg which was more significant com-
pared not only with control group, but with comparison to group treated with diazepam (p<0.05). Chronic treatment 
with PK-2123 or PK-2122 in all tested doses produced anxiolytic-like effect (p<0.05), compared with control group 
and diazepam group. These results demonstrate that PK-2126, but not PK-2122, is dose independent and may be 
effective in experimental model of anxiety in rats when administered acutely or repeatedly. 
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Introduction
Anxiety disorders are a common and debilitat-
ing mental illnesses. Current pharmacological 
treatments have limitations including resis-
tance, delayed efficacy and side effects [1, 2]. 
Better understanding the novel neurotransmit-
ter pathways and the interplay between these 
systems is broadening the scope of anxiolytic 
drug treatments [1].
The dopamine (DA) pathway is activated by 
stress, and this response has as a corollary on 
the induction of stress-related behaviors such 
as anxiety [3]. A number of clinical observa-
tions led to the hypothesis that DA dysfunction 
may play a role in social anxiety disorder [4]. 
Tentative evidence of involvement of DA in anxi-
ety disorders comes from a study measuring 
the catecholamine concentrations in patients 
[3]. Human studies of DA and its metabolites 
have reported reduced cerebrospinal fluid (CSF) 
homovanillic acid (HVA) levels in patients with 
panic disorder with comorbid social anxiety 
compared with panic disorder patients, as well 
as correlations between low CSF HVA and mea-
sures of introversion [5]. Although the use of 
animal models to study the role of DA in social 
anxiety has inherent problems because of the 
interactional nature of the disorder, some stud-
ies have suggested that reduced DA function is 
associated with increased anxiety [3, 6, 7]. A 
strain of timid mice with reduced DA levels is 
available, and DA depletion results in increased 
anxiety [5]. The DA receptors have been impli-
cated in anxiety mechanisms by preclinical evi-
dence from behavioral studies [1, 8, 9]. 
However information about the role of DA in 
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anxiety remains scarce. Therefore, novel psy-
chotropic drugs based on the structure of dopa-
mine for the treatment and prevention of a 
number of affective disorders are vital to the 
ongoing treatment of such disorders. In this 
regard, the department of Neuropharmacology 
of Institute for Experimental Medicine (St. 
Petersburg, Russia) synthesized novel dopami-
nergic substances; -3,4-dimethoxyphenylethyl-
amine derivates. 
Thus, the aim of the present study was to 
explore the anxiolytic-like effects of these novel 
3,4-dimethoxyphenylethylamine derivates after 
acute or chronic treatment in rats. In the pres-
ent experiments, a comparison between acute 
and chronic treatment was made in order to 
evaluate the possible change of drug efficacy 
depending on a repeated administration and 
on those of a clinically effective anxiolytic, 
diazepam.
for Animal Research, Pavlov Institute of 
Physiology.
All animals were gently handled by experienced 
keepers from the facility each day for a week 
prior to experimental procedures. Any environ-
mental or physical stress was avoided in order 
to habituate the rats to manual handling. 
Animals were randomly assigned to experimen-
tal groups and were used only once in the 
behavioral experiments.
3,4-Dimethoxyphenylethylamine derivates and 
treatment
The following 3,4-dimethoxyphenylethylamine 
derivates were tested in this study (Figure 1): 
PK-2111 (N-L-tyrozyl-3,4-dimethoxyphenylethy- 
lamine oxalate monohydrate), PK-2122 (N-L-tri- 
ptophanyl-3,4-dimethoxyphenylethylamine ox- 
alate trihydrate), PK-2123 (N-β-alanyl-3,4-di- 
methoxyphenylethylamine oxalate) and PK- 
Figure 1. Structure of novel 3,4-dimethoxyphenylethylamine derivates.
Methods
Animals
Male rats (Wistar strain, 
purchased from Rappo- 
lovo, Russia, 180-220 g) 
were used. For at least 
one week prior to the 
experiments, the rats 
were housed six to a cage 
under standard environ-
mental conditions: con-
stant temperature of 23 ± 
1°C, 60% humidity, 12-h 
light/dark cycle (light on 
8:00 a.m.), food and water 
ad libitum. All experiments 
were carried out in accor-
dance with the guide for 
care and use of Laboratory 
Animals published by the 
National Institute of Hea- 
lth (National Research 
council, publication No 
85-23, revised in 1996), 
and the Animal Welfare 
Assurance Renewal for 
Pavlov Institute of Phy- 
siology. The rationale, de- 
sign and methods of this 
study have been approved 
by the Ethical Committee 
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2126 (N-L-glycyl-3,4-dimethoxyphenylethylami- 
ne hydrochloride). 
Animals were randomly assigned to any experi-
mental groups and were used only once in the 
behavioral experiments. For each behavioral 
test the rats were assigned to 14 independent 
groups (n = 7 in each group). The control group 
received only the vehicle in which 3,4-dime-
thoxyphenylethylamine derivates were dis-
solved (0.9% NaCl solution), another 12 groups 
received PK-2111 or PK-2122 or PK-2123 or 
PK-2126 in several doses (0.1, 1.0, 10.0 mg/
kg) and the last group received 1.0 mg/kg of 
diazepam (Nycomed, Denmark), which is effec-
tive to exert an anxiolytic-like effect in the black 
and white model (BWM) [10]. The investigated 
substances and diazepam were freshly diluted 
in physiological saline and injected intraperito-
neally (i.p.) acutely (1 h prior to behavioral test-
ing) or chronically (for 21 days, the last injection 
being made 1 h prior to behavioral testing) in 
h (initiating dark phase) and left for 1 h to accli-
matize to the novel surroundings. The BWM 
was initiated at 19:00 h, 1 h after initiating the 
dark phase. After this duration, each rat was 
placed into the middle of the black compart-
ment facing the doorway, and the behavioral 
activity measured for 5 min. The variables were: 
a) latency to the first entry into the white com-
partment (the time taken after initial placement 
of a rat in the black compartment until it 
crossed completely to the white compartment); 
b) time spent in the white compartment (the 
sum of all time periods in the white compart-
ment), and c) frequency of entries into the white 
compartment (the total number of entries to 
the white compartment) as previously described 
[10]. A video camera was installed above the 
model to record rat activity in the maze. Two 
independent observes measured the behavior-
al variables. Additionally, the frequency and 
time spent in the exploration toward white com-
partment was evaluated, assuming exploration 
Figure 2. Effects of novel 3,4-dimethoxyphenylethylamine derivates after acute 
administration on the time spent into white compartment and the latency to first 
entry of experimental groups in the BWM. Columns represent the time spent 
in white compartment (A) mean ± SEM (in sec) and latency to first entry into 
white compartment (B) mean ± SEM (in sec). Each group comprised a mini-
mum of seven rats. *-P < 0.05 vs control group of rats, **-P < 0.05 vs rats 
treated with diazepam, #-P < 0.05 vs 0.1 mg/kg dose level group, ##--P < 0.05 
vs 1.0 mg/kg dose level group.
animals subjected to BWM 
and open field test (OFT). 
Behavioral tests
Black and white model 
(BWM): The BWM has been 
broadly validated as a useful 
tool for anxiety study and for 
the screening of anxiolytic 
and anxiogenic drugs [11]. 
The dimensions of BWM 
were 80 × 40 × 40 cm [10]. 
The box was further divided 
in two equal chambers (40 × 
40 × 40 cm) by a barrier pos-
sessing a doorway (10 × 10 
cm) that allows the rats to 
cross freely from one cham-
ber to another. The black 
compartment was not illumi-
nated, whereas the white 
compartment was complete-
ly illuminated by a 40 W 
white light. A video camera 
was installed above the illu-
minated compartment to 
record rat activity. Later, two 
independent observers mea-
sured the behavioral vari-
ables. On the day of test, the 
rats were brought to the 
experimental room at 18:00 
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when the rat was leaning out of the white com-
partment (that is, until the head and half of the 
body was into the white compartment without 
crossing completely to the illuminated compart-
ment). After BWM test, the rat was immediately 
submitted to the Open Field Test (OFT).
OFT: To evaluate the effect of new substances 
on spontaneous locomotor activity, grooming, 
and rearing, each rat was individually submit-
ted to a 5-min period to the OFT. An opaque 
plexiglass cage (44 × 33 cm) with walls 20-cm 
in height was used. The floor was divided into 
12 squares (11 × 11 cm). A video camera was 
installed above the model to recode the rat 
activity in the maze. Two independent observes 
measured the behavioral variables. The gener-
al locomotor activity of the rats associated with 
treatments was evaluated, which could inter-
fere with the behavioral activity of the rats in 
the BWM. No other measures were evaluated.
At the beginning of the test, the rat was gently 
placed in a corner of the cage, and such vari-
ables measured: the number of squares 
crossed by the rat (crossing), assuming cross-
Statistical analysis
All data were analyzed using one-way ANOVA 
and the post-hoc Dunnett’s test for multiple 
comparisons to control. The paired Student’s 
t-test was used for intra-group comparisons. A 
P-value of 0.05 or less was considered as indic-
ative of a significant difference. All values were 
expressed as mean ± S.E.M. 
Results
Effects of acute administration of novel 3,4-di-
methoxyphenylethylamine derivates on anxi-
ety-like behavior in the BWM
No differences in the frequency of entries into 
the white compartment among the control 
group, diazepam treatment and different doses 
of novel dopaminergic substances after acute 
administration [F(5,72) = 1.92, P = 0.11, NS] 
were observed. However, a significant differ-
ence in the time spent into the white compart-
ment [F(5,72) = 21.95, P < 0.001], in the laten-
cy to the first entry into the white compartment 
Figure 3. Effects of novel 3,4-dimethoxyphenylethylamine derivates after acute 
administration on the time spent into white compartment and the latency to 
first entry of experimental groups in the BWM. Columns represent the time 
spent in white compartment (A) mean ± SEM (in sec) and latency to first en-
try into white compartment (B) mean ± SEM (in sec). Each group comprised 
a minimum of seven rats. *-P < 0.05 vs control group of rats, **-P < 0.05 vs 
rats treated with diazepam, #-P < 0.05 vs 0.1 mg/kg dose level group, ##--P 
< 0.05 vs 1.0 mg/kg dose level group.
ing when an animal passed 
from one square to another 
with its rear legs; frequency 
of rearing, assuming rearing 
when the rat acquired a verti-
cal posture with respect to the 
cage floor; frequency of groom-
ing included paw licking, nose/
face grooming (strokes along 
the snout), head washing 
(semicircular movements over 
the top of the head and behind 
the ears), body grooming/
scratching (body fur licking and 
scratching the body with the 
hind paws), leg licking, and 
tail/genitals grooming (licking 
of the genital area and tail) as 
previously described by others 
[12].
After each test session, the 
BWM and OFT cage were care-
fully cleaned and deodorized 
with a cleaning solution 
(ammonia 0.5%, ethanol 15%, 
extran 10%, isopropyl alcohol 
5%, antiseptic with aromatiz-
ing 19%, and distillated water 
50.5%).
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[F(5,72) = 15.22, P < 0.003], in the time spent 
in exploration toward white compartment 
[F(5,72) = 9.40, P < 0.001] and in the frequency 
of explorations toward white compartment 
[F(5,72) = 14.52, P < 0.001] were observed 
among the different treatments. Diazepam (1.0 
mg/kg) significantly increased the time spent 
into the white compartment, the time spent in 
exploration toward white compartment and the 
frequency of explorations toward white com-
partment, but reduced the latency to the first 
entry into the white compartment compared to 
the control group (P < 0.05, Figures 2A, 2B, 3A 
and 3B). 
The time spent into the white compartment, the 
time spent in exploration toward white com-
partment and the frequency of explorations 
toward white compartment were reduced after 
PK-2111 administration in all tested doses 
compared with the control group (P < 0.05, 
Figures 2A, 2B, 3A and 3B). Moreover, a 
decrease of the time spent into the white com-
reduced after PK-2122 0.1 mg/kg compared to 
the control group (P < 0.05, Figures 2A, 2B, 3A 
and 3B). However, administration of PK-2122 in 
the middle dose (1.0 mg/kg) or in the high dose 
(10.0 mg/kg) significantly increased the time 
spent into the white compartment, the time 
spent in exploration toward white compartment 
and the frequency of explorations toward white 
compartment compared to the control group (P 
< 0.05, Figures 2A, 2B, 3A and 3B). An increase 
of the time spent into the white compartment, 
the time spent in exploration toward white com-
partment and the frequency of explorations 
toward white compartment after PK-2122 
administration in the largest dose (10.0 mg/kg) 
was significantly increased compared to 1.0 
mg/kg dose level of this group. Also, the laten-
cy to the first entry into the white compartment 
was increased after of PK-2122 administration 
in the small dose (0.1 mg/kg) compared to the 
control group (P < 0.05, Figure 2A). On the con-
trary, administration of PK-2122 in the middle 
dose (1.0 mg/kg) or in the high dose (10.0 mg/
Figure 4. Effects of novel 3,4-dimethoxyphenylethylamine derivates after re-
peated administration on the time spent in white compartment and the latency 
to first entry of experimental groups in the BWM. Columns represent the time 
spent in white compartment (A) mean ± SEM (in sec) and latency to first en-
try into white compartment (B) mean ± SEM (in sec). Each group comprised 
a minimum of seven rats. *-P < 0.05 vs control group of rats, **-P < 0.05 vs 
rats treated with diazepam, #-P < 0.05 vs 0.1 mg/kg dose level group, ##--P 
< 0.05 vs 1.0 mg/kg dose level group.
partment, the time spent in 
exploration toward white com-
partment and the frequency 
of explorations toward white 
compartment after PK-2111 
administration in the middle 
dose (1.0 mg/kg) or in the 
high dose (10.0 mg/kg) was 
more significant compared to 
0.1 mg/kg dose level of this 
group. Concurrently, the laten-
cy to the first entry into the 
white compartment after all 
doses of PK-2111 was 
increased compared to the 
control group (P < 0.05, 
Figure 2A). The increase of 
the latency to the first entry 
into the white compartment 
after the middle dose (1.0 
mg/kg) or the high dose (10.0 
mg/kg) of PK-2111 was sig-
nificantly increased compared 
to 0.1 mg/kg dose level of 
this group. 
The time spent into the white 
compartment, the time spent 
in exploration toward white 
compartment and the fre-
quency of explorations toward 
white compartment were 
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kg) significantly reduced the latency to the first 
entry into the white compartment compared to 
the control group (P < 0.05, Figure 2A). 
Moreover, a decrease of the latency to the first 
entry into the white compartment after PK-2122 
administration in the high dose was significant-
ly increased compared to 1.0 mg/kg dose level 
of this group.
All doses of PK-2126 increased the time spent 
into the white compartment, the time spent in 
exploration toward white compartment and the 
frequency of explorations toward white com-
partment and decreased the frequency of 
explorations toward white compartment com-
pared to the control group (P < 0.05, Figures 
2A, 2B, 3A and 3B). 
However, all tested doses of PK-2123 failed to 
change the time spent into the white compart-
ment, the latency to the first entry into the white 
compartment, the time spent in exploration 
toward white compartment and the frequency 
0.001] and in the frequency of explorations 
toward white compartment [F(5,72) = 15.11, P 
< 0.001] among the different treatments were 
observed. Also, diazepam (1.0 mg/kg) signifi-
cantly increased the time spent into the white 
compartment, the time spent in exploration 
toward white compartment and the frequency 
of explorations toward white compartment, but 
reduced the latency to the first entry into the 
white compartment compared to the control 
group (P < 0.05, Figures 4A, 4B, 5A and 5B). 
After repeated administration of PK-2111 0.1 
and 1.0 mg/kg significantly increased the time 
spent into the white compartment, the time 
spent in exploration toward white compartment 
and the frequency of explorations toward white 
compartment compared to the control group 
and group receiving diazepam (P < 0.05, 
Figures 4A, 4B, 5A and 5B). The repeated 
administration of PK-2111 in the high dose sig-
nificantly increased the time spent into the 
white compartment, the time spent in explora-
Figure 5. Effects of novel 3,4-dimethoxyphenylethylamine derivates after repeated 
administration on the time spent in white compartment and the latency to first 
entry of experimental groups in the BWM. Columns represent the time spent in 
white compartment (A) mean ± SEM (in sec) and latency to first entry into white 
compartment (B) mean ± SEM (in sec). Each group comprised a minimum of 
seven rats. *-P < 0.05 vs control group of rats, **-P < 0.05 vs rats treated with 
diazepam, #-P < 0.05 vs 0.1 mg/kg dose level group, ##--P < 0.05 vs 1.0 mg/kg 
dose level group.
of explorations toward 
white compartment com-
pared to the control group.
Effects of chronic admin-
istration of novel 3,4-di-
methoxyphenylethylamine 
derivates on anxiety-like 
behavior in the BWM
No significant differences 
in the frequency of entries 
into the white compart-
ment among the control 
group, diazepam treat-
ment and different doses 
of novel dopaminergic sub- 
stances after repeated 
administration were obser- 
ved [F(5,72) =23.22, P = 
0.3, NS].
Significant differences in 
the time spent into the 
white compartment [F 
(5,72) = 7.20, P < 0.001], 
in the latency to the 
first entry into the white 
compartment [F(5,72) = 
14.95, P<0.003], in the 
time spent in exploration 
toward white compart-
ment [F(5,72) = 2.97, P < 
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tion toward white compartment and the fre-
quency of explorations toward white compart-
ment compared to the control group. Moreover, 
an increase of the time spent into the white 
compartment, the time spent in exploration 
toward white compartment and the frequency 
of explorations toward white compartment 
after PK-2111 administration in the high dose 
(10.0 mg/kg) was less effective compared to 
0.1 mg/kg or 1.0 mg/kg dose levels of this 
group. 
Rats treated with PK-2122 in all tested doses 
significantly spent more time in the white com-
partment compared to the control and diaze-
pam group (P < 0.05, Figure 4A). Also, these 
rats demonstrated significantly increased time 
spent in exploration toward white compartment 
and the frequency of explorations toward white 
compartment compared to the control and 
diazepam group (P < 0.05, Figure 5A and 5B). 
Moreover, the rats treated with PK-2122 in all 
tested doses had significantly reduced latency 
period to the first entry to the white compart-
ment compared to the control and diazepam 
group (P < 0.05, Figure 4B).
In contrast, chronic administration of PK-2126 
in all tested doses failed to modify the time 
spent into the white compartment, the latency 
of the first entry into the white compartment, 
middle dose (1.0 mg/kg) were significantly 
higher compared to 0.1 mg/kg dose level of 
this group, and the same parameters after 
PK-2123 administration in the high dose (10.0 
mg/kg) were significantly less compared to 0.1 
mg/kg or 1.0 mg/kg dose levels of this group. 
Also, PK-2123 significantly decreased the 
latency to the first entry to the white compart-
ment compared to the control group and group 
receiving diazepam (P < 0.05, Figure 4B). The 
decrease of the latency to the first entry to the 
white compartment after PK-2123 administra-
tion in the middle dose (1.0 mg/kg) was signifi-
cantly higher compared to 0.1 mg/kg dose 
level of this group, and the same parameter 
after PK-2123 administration in the high dose 
(10.0 mg/kg) was significantly less compared 
to 0.1 mg/kg or 1.0 mg/kg dose levels of this 
group.
Effects of acute administration of novel 3,4-di-
methoxyphenylethylamine derivates on behav-
ior in the OFT
No significant differences in the crossing of the 
rats treated with different substances were 
observed [F(5,72) = 2.23, P > 0.09]. However, 
significant differences in the rearing and groom-
ing between drug treatments were observed 
([F(5,72) = 11.56, P < 0.05], [F(5,72) = 8.01, P 
< 0.002], respectively) and rats treated with 
Table 1. Effects of novel 3,4-dimethoxyphenylethylamine deri-
vates after acute administration on behavior in the open field 
test for 5 min
Groups Crossing Rearing Grooming
Control 42.0 ± 3.6 13.5 ± 1,8 2.4 ± 0.4
PK-2111 0.1 mg/kg 39.5 ± 2.6 6.7 ± 0.6* 1.0 ± 0.2*
PK-2111 1.0 mg/kg 46.2 ± 3.2 7.0 ± 0.6* 1.2 ± 0.2*
PK-2111 10.0 mg/kg 40.7 ± 2.8 12.4 ± 1.2** 3.0 ± 0.2**
PK-2122 0.1 mg/kg 68.4 ± 5.6*,** 6.0 ± 0.8* 1.0 ± 0.2*
PK-2122 1.0 mg/kg 44.6 ± 4.4 20.6 ± 2.8*,**,# 7.6 ± 0.2*,**,#
PK-2122 10.0 mg/kg 76.8 ± 3.8*,**,# 6.2 ± 0.8* 1.1 ± 0.4*
PK-2123 0.1 mg/kg 39.5 ± 2.6 6.7 ± 0.6* 1.0 ± 0.2*
PK-2123 1.0 mg/kg 46.2 ± 3.2 7.0 ± 0.6* 1.2 ± 0.2*
PK-2123 10.0 mg/kg 40.7 ± 2.8 12.4 ± 1.2** 3.0 ± 0.2**
PK-2126 0.1 mg/kg 68.4 ± 5.6*,** 6.0 ± 0.8* 1.0 ± 0.2*
PK-2126 1.0 mg/kg 44.6 ± 4.4 20.6 ± 2.8*,**,# 7.6 ± 0.2*,**,#
PK-2126 10.0 mg/kg 76.8 ± 3.8*,**,# 6.2 ± 0.8* 1.1 ± 0.4*
Diazepam 1.0 mg/kg 41.2 ± 3.8 21.3 ± 1.4* 4.1 ± 0.6*
Each group comprised a minimum of seven rats. *-P < 0.05 vs control group of 
rats, **-P < 0.05 vs rats treated with diazepam, #-P < 0.05 vs 0.1 mg/kg dose 
level group, ##--P < 0.05 vs 1.0 mg/kg dose level group.
the time spent in exploration 
toward white compartment and 
the frequency of explorations 
toward white compartment com-
pared to the control group (post-
hoc, P > 0.05, Figures 4A, 4B, 5A 
and 5B). 
PK-2123 in all tested doses sig-
nificantly increased the time 
spent into the white compart-
ment, the time spent in explora-
tion toward white compartment 
and the frequency of explorations 
toward white compartment com-
pared to the control and diaze-
pam group (P < 0.05, Figures 4A, 
4B, 5A and 5B). The increase of 
the time spent in the white com-
partment, the time spent in explo-
ration toward white compartment 
and the frequency of explorations 
toward white compartment after 
PK-2123 administration in the 
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diazepam (1.0 mg/kg) had significantly 
increased the frequency of rearing and the fre-
quency of grooming compared to the control 
rats (P < 0.05, Table 1). 
All tested doses of PK-2111 reduced the fre-
quency of rearing and the frequency of groom-
ing compared to the control group (P < 0.05, 
Table 1). The decrease of the frequency of rear-
ing and the frequency of grooming after 
PK-2111 administration in the middle dose (1.0 
mg/kg) or in the high dose (10.0 mg/kg) was 
significantly increased compared to 0.1 mg/kg 
dose level of this group.
Low dose administration of PK-2122 (0.1 mg/
kg) reduced the frequency of rearing and the 
frequency of grooming compared to the control 
group (P < 0.05, Table 1). However, administra-
tion of PK-2122 in the middle dose or in the 
high dose significantly increased the frequency 
of rearing and the frequency of grooming com-
pared to the control group (P < 0.05, Table 1). 
Moreover, an increase of the frequency of rear-
ing and the frequency of grooming after 
PK-2122 administration in the high dose (10.0 
mg/kg) was more significantly compared to 1.0 
mg/kg dose level of this group.
All doses of PK-2126 significantly increased the 
frequency of rearing and the frequency of 
0.002], respectively) and rats treated with diaz-
epam (1.0 mg/kg) had significantly increased 
frequency of rearing and the frequency of 
grooming compared to the control rats (P < 
0.05, Table 2).
After repeated administration of PK-2111 0.1 
and 1.0 mg/kg, the frequency of rearing and 
the frequency of grooming were significantly 
increased compared to the control and diaze-
pam group (P < 0.05, Table 2). The repeated 
administration of PK-2111 in the high dose also 
significantly increased the frequency of rearing 
and the frequency of grooming compared to 
control. Moreover, an increase of the frequency 
of rearing and the frequency of grooming after 
PK-2111 administration in the high dose was 
less effective compared to 0.1 mg/kg or 1.0 
mg/kg dose levels of this group. 
The frequency of rearing and the frequency of 
grooming after repeated administration of 
PK-2123 were significantly increased com-
pared to the control and diazepam groups (P < 
0.05, Table 2). The increase of frequency of 
rearing and the frequency of grooming after 
PK-2123 administration in the middle dose 
were significantly higher compared to 0.1 mg/
kg dose level of this group, and the same 
parameters after PK-2123 administration in 
Table 2. Effects of novel 3,4-dimethoxyphenylethylamine de-
rivates after repeated administration on behavior in the open 
field test for 5 min
Groups Crossing Frequency of Rearing
Frequency of 
Grooming
Control 39.1 ± 2.4 13.1 ± 1.8 2.2 ± 0.4
PK-2111 0.1 mg/kg 40.5 ± 2.6 33.4 ± 1.2*,** 5.4 ± 0.2*,**
PK-2111 1.0 mg/kg 43.2 ± 3.2 31.8 ± 1.6*,** 5.2 ± 0.2*,**
PK-2111 10.0 mg/kg 46.7 ± 2.8 22.4 ± 1.2*,#,## 3.7 ± 0.2*,#,##
PK-2122 0.1 mg/kg 43.2 ± 3.2 32.5 ± 1.2*,** 5.0 ± 0.4*,**
PK-2122 1.0 mg/kg 39.6 ± 4.4 29.6 ± 1.6*,** 4.9 ± 0.2*,**
PK-2122 10.0 mg/kg 43.2 ± 3.2 32.3 ± 1.7*,** 5.6 ± 0.2*,**
PK-2123 0.1 mg/kg 39.5 ± 2.6 34.7 ± 1.7*,** 6.3 ± 0.8*,**
PK-2123 1.0 mg/kg 47.2 ± 3.2 46.5 ± 2.1*,**,# 7.6 ± 0.8*,**,#
PK-2123 10.0 mg/kg 38.7 ± 2.8 29.3 ± 0.8*,**,#,## 4.8 ± 0.4*,**,#,##
PK-2126 0.1 mg/kg 42.9 ± 1.4 13.5 ± 1.6 2.4 ± 0.2
PK-2126 1.0 mg/kg 39.3 ± 2.4 12.7 ± 1.6 2.6 ± 0.2
PK-2126 10.0 mg/kg 40.1 ± 3.2 13.8 ± 1.8 2.3 ± 0.4
Diazepam 1.0 mg/kg 43.4 ± 3.8 22.8 ± 1.8* 3.9 ± 0.4*
Each group comprised a minimum of seven rats. *-P < 0.05 vs control group 
of rats, **-P < 0.05 vs rats treated with diazepam, #-P < 0.05 vs 0.1 mg/kg 
dose level group, ##--P < 0.05 vs 1.0 mg/kg dose level group.
grooming compared to control (P < 
0.05, Table 1).
Neither 0.1 mg/kg or 1.0 mg/kg, or 
1.0 mg/kg doses of PK-2123 modi-
fied the frequencies of rearing and 
grooming in the OFT compared to 
the control group (P > 0.05, Table 
1).
Effects of chronic administration 
of novel 3,4-dimethoxyphenylethyl-
amine derivates on behavior in the 
OFT
No significant differences in the 
crossing of the rats treated with 
different substances after the 
repeated administration were ob- 
served [F(5,72) = 1.48, P > 0.2]. 
Yet, a significant difference in the 
frequency of rearing and frequency 
of grooming between drug treat-
ments after the repeated adminis-
tration was affirmed ([F(5,72) = 
4.17, P < 0.05], [F(5,72) = 9.40, P < 
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the high dose were significantly less compared 
to 0.1 mg/kg or 1.0 mg/kg dose levels of this 
group.
Repeated administration of PK-2122 in all 
doses significantly increased the frequency of 
rearing and the frequency of grooming com-
pared to the control and diazepam groups (P < 
0.05, Table 2).
Neither 0.1 mg/kg or 1.0 mg/kg, or 1.0 mg/kg 
doses of PK-2126 modified the frequencies of 
rearing and grooming in the OFT compared to 
control (P > 0.05, Table 2).
Discussion
The Dopamine (DA) pathway is activated by 
stress, and this response has as a corollary in 
the induction of stress-related behaviors such 
as anxiety [3]. A number of clinical observations 
led to the hypothesis that DA dysfunction may 
play a role in social anxiety disorder [4]. The 
search and development of new psychotropic 
drugs based on the structure of DA for the treat-
ment and prevention of affective disorders are 
of great interest, and in this regard, a series of 
novel substances on basis of DA structure has 
been developed: PK-2111, PK-2122, PK-2123, 
PK-2126.
In this study, the anxiolytic-like effects of such 
compounds in rats in the BWM and the OFT 
were explored, and were compared with 
diazepam.
The BWM has been useful to screen substanc-
es with anxiolytic or anxiogenic potency [11, 
13]. An anxious animal increases the latency to 
the first entry to the white compartment and 
reduces the time spent in this compartment 
[11, 14]. On the contrary, animals treated with 
anxiolytic drugs (diazepam or alprazolam) spent 
more time in the white compartment [14, 15], 
which suggests an anxiolytic-like effect. In this 
study, the rats treated with diazepam (1.0 mg/
kg) had a short latency to the first entry to the 
white compartment and spent more time in it, 
compared to control. Bradley et al. [16] report-
ed that acute or chronic administration of diaz-
epam (1.0 mg/kg, i.p.) increased the explora-
tion toward the white compartment, decreased 
the latency to the first entry to this compart-
ment, and increased the time spent in it, which 
is in accordance with the effect produced by 
anxiolytic substances in the BWM [15]. In the 
BWM, it is possible to detect false anxiolytic 
effects when drugs increase general locomo- 
tor activity. For example, methamphetamine 
enhances transitions between black-white 
compartments and increases the time spent in 
the white compartment; however, it was associ-
ated with a general locomotor hyperactivity [11, 
14]. Therefore, this behavioral change in the 
BMW is not related with an anxiolytic-like 
effect; rather, it is a psychostimulant effect [14, 
15]. In this study, in rats treated with diazepam, 
the reduced latency to entry, the increased 
time spent into the white compartment, and 
the increased exploration toward it were not 
related with a general locomotor hyperactivity, 
because diazepam did not induce any increase 
in crossing in the OFT. The findings are support-
ed by previous reports that anxiolytic drugs 
such as diazepam increases the time spent in 
the white compartment in the BWM, without 
producing significant changes in locomotion in 
the OFT [17, 18]. In some cases, grooming 
abnormally increases in low-stressed rats [19, 
20], and contrarily, in animals submitted to 
high-stress such as electric footshock, groom-
ing is diminished significantly [21]. This reduc-
tion of grooming is prevented by anxiolytic 
drugs returning it to control [22]. In the study 
presented here, rats treated with diazepam 
spent more time in grooming in the OFT as com-
pared to control. In this connection, a brightly 
illuminated compartment (in the BWM) produc-
es anxiety in the animals [11]. Therefore, when 
rats treated with saline are evaluated in the 
OFT (after BWM test) they reduce grooming 
probably as a consequence of stress generated 
in the BWM. The rats treated with diazepam 
prevented the reduction of grooming in the OFT 
which is consistent with the effect of anxiolytic 
drugs (alprazolam and diazepam) on grooming 
in stressed rats [22]. Additionally, rats treated 
with diazepam had an increased rearing as 
compared with the control group which is inter-
preted as indicator of exploration; an effect 
enhanced by anxiolytic substances in the OFT 
[23]. 
In this study, we found that the behavioral 
effects of the novel 3,4-dimethoxyphenylethyl-
amine derivates on anxiety-like behavior are 
depended on type of treatment (acute or 
repeated). The results obtained from the BWM 
and the OFT tests showed that the acute admin-
istration of all tested doses (0.1, 1.0 or 10 mg/
kg) of PK-2126 induced anxiolytic-like effect in 
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rats. The acute administration of 0.1, 1.0 or 10 
mg/kg doses of PK-2111 was followed by an 
anxiogenic-like effect compared with control. 
Also, the anxiogenic-like effect of the middle 
and the high doses of PK-2111 was more effec-
tive that with low dose of PK-2111. In contrast, 
acute administration of PK-2123 in all doses 
failed to produce any effect on anxiety-like 
behavior in the BWM and the behavioral reac-
tions in the OFT. Indeed, an interesting result of 
the present experiments are the different 
effects for small dose (0.1 mg/kg) and for mid-
dle or high doses (1.0 and 10.0 mg/kg) of 
PK-2122 when it acutely administered on the 
behavioral parameters in the BWM and the OFT 
tests. In dose of 0.1 mg/kg, PK-2122 exerted 
anxiogenic-like effect, while in doses of 1.0 or 
10.0 mg/kg, PK-2122 exerted anxiolytic-like 
effect compared with the control group. In fact, 
anxiolytic-like effect of PK-2122 in dose of 10.0 
mg/kg dose was higher than it in a dose of 1.0 
mg/kg.
The repeated treatment with PK-2111 was fol-
lowed by an anxiolytic-like effect in doses of 0.1 
or 1.0 mg/kg which was more profound com-
pared to both control and diazepam group. 
Also, chronic treatment of PK-2111 in the high 
dose (10.0 mg/kg) induced anxiolytic-like 
effect compared with the control group, and 
this effect was less effective than it in a doses 
of 0.1 and 1.0 mg/kg. Chronic treatment with 
PK-2123 was followed by an anxiolytic-like 
effect in all doses which was significant com-
pared with control group and group treated with 
diazepam. The decrease of anxiety-like behav-
ior after PK-2123 administration in the middle 
dose was significantly higher compared to 0.1 
mg/kg dose, and the same parameter was sig-
nificantly less compared to 0.1 mg/kg or 10.0 
mg/kg doses. Also, chronic treatment of 
PK-2123 in the high dose induced anxiolytic-
like effect compared with the control group, 
and this effect was less effective than it in 
another doses. The results received from the 
BWM and the OFT tests showed that the chron-
ic PK-2122 administration in all tested doses 
induced anxiolytic-like effect in rats. In con-
trast, chronic PK-2126 administration in all 
doses failed to produce any effect on anxiety-
like behavior in the BWM and the behavioral 
reactions in the OFT.
Taken together these finding support the 
effects of the novel 3,4-dimethoxyphenylethyl-
amine derivates after acute treatment on anxi-
ety-like behavior are inverse after repeated 
treatment. The results can be summarized as 
follows: a) acute administration of PK-2126 
exerted anxiolytic-like effect in the BWM and 
increased the rearing and grooming in a man-
ner similar to diazepam, while repeated admin-
istration of PK-2126 failed to modify anxiety-
like behavior in the BWM and behavioral reac-
tions in the OFT; b) acute administration of 
PK-2123 failed to modify an anxiety-like behav-
ior in the BWM and behavioral reactions in the 
OFT, while the repeated administration of 
PK-2123 exerted anxiolytic-like effect in the 
BWM, and increased the rearing and grooming 
which are exceeded the effect of diazepam; c) 
acute administration of PK-2111 induced anx-
iogenic-like effect in the BWM and decreased 
the rearing and grooming in the OFT, while 
repeated administration of PK-2111 produced 
anxiolytic-like effect in the BWM and increased 
the rearing and grooming which exceeded the 
effect of diazepam; d) acute administration of 
PK-2122 in small dose induced anxiogenic-like 
effect in the BWM, and decreased the rearing 
and grooming in the OFT; and in the middle and 
high doses of PK-2122 induced anxiolytic-like 
effect in the BWM and increased the rearing 
and grooming in the OFT, while repeated admin-
istration of PK-2122 in all doses produced anx-
iolytic-like effect in the BWM and increased the 
rearing and grooming which are exceeded the 
effect of diazepam. 
Further studies exploring the participation of 
D1- and D2-receptors in the anxiolytic-like and 
anxiogenic-like effects of novel 3,4-dimethoxy-
phenylethylamine derivates should be under- 
taken.
Conclusions
In conclusion, these results suggest that acute 
or repeated administration of PK-2126 and 
PK-2122 may be effective in experimental 
model of anxiety in rats Further research is 
needed to elucidate the mechanisms by which 
these compounds affect the dopaminergic sys-
tem, and if there is potential for these com-
pounds in the clinicalarena.
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